Norleual

Research use only, not for human use.

Angiotensin IV analog. Highly potent HGF/c-MET inhibitor (IC50 = 3 pM). Inhibits HGF-induced MDCK cell proliferation and invasion in vitro. Also AT4 receptor antagonist; disrupts LTP stabilization. Antiangiogenic.

Angiotensin IV analog. Highly potent HGF/c-MET inhibitor (IC50 = 3 pM). Inhibits HGF-induced MDCK cell proliferation and invasion in vitro. Also AT4 receptor antagonist; disrupts LTP stabilization. Antiangiogenic.

Norleual at 20 and 50 pM significantly reduces HGF-dependent c-Met and Gab1 phosphorylation. 20 pM Norleual dramatically reduces HGF-initiated association between Gab1 and c-Met in HEK293 cells. Norleual markedly attenuates HGF-dependent c-Met activation and downstream signaling.Norleual (1 pM-1 μM; 4 days) is able to inhibit HGF-dependent signaling, proliferation, migration, and invasion in multiple cell types at concentrations in the picomolar range in MDCK cells.

Norleual (50 μg/kg; intraperitoneal injection; daily; for 2 weeks; C57BL/6 mice) suppresses pulmonary colonization by B16-F10 murine melanoma cells.

——

GPCR/G Protein

Angiotensin Receptor

——

——

——

334994-34-2

774.95

C41H58N8O7

>98% (HPLC)

water:2 mg/mL

[H]N(C(CC1=CC=C(O)C=C1)C(=O)N[C@H](CN[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O)CC(C)C)C(=O)[C@@H](N)CCCC

——

(-20℃)

With Ice Pack

≥ 2 years